A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature

Cancer Genetics and Cytogenetics

Volumn 179, Issue 2, 2007, Pages 89-92

  Ghataorhe, Pavandeep ^a   Kurian, Allison W ^b   Pickart, Angela ^c   Trapane, Pamela ^d   Norton, Jeffrey A ^b   Kingham, Kerry ^b   Ford, James M ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Children's Hospital of Wisconsin   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRCA2 GENE; BREAST CANCER; CANCER SUSCEPTIBILITY; FAMILIAL CANCER; GENE IDENTIFICATION; GENE MUTATION; GERM LINE; HUMAN; HYPERPARATHYROIDISM; INCIDENCE; MALE BREAST CANCER; MEN1 GENE; NEUROENDOCRINE TUMOR; OVARY CANCER; PANCREAS ADENOCARCINOMA; PENETRANCE; PRIORITY JOURNAL; TUMOR GENE;

ADENOCARCINOMA; ADULT; CARCINOMA, NEUROENDOCRINE; FAMILY HEALTH; FEMALE; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; HYPERTHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA; PANCREATIC NEOPLASMS; PEDIGREE; PROTO-ONCOGENE PROTEINS;

EID: 36148936352     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.08.009     Document Type: Article

References (27)

1. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Frye C., Hattier T., Phelps R., Haugen-Strano A., Katcher H., Yakumo K., Gholami Z., Shaffer D., Stone S., Bayer S., Wray C., Bogden R., Dayananth P., Ward J., Tonin P., Narod S., Bristow P.K., Norris F.H., Helvering L., Morrison P., Rosteck P., Lai M., Barrett J.C., Lewis C., Neuhausen S., Cannon-Albright L., Goldgar D., Wiseman R., Kamb A., and Skolnick M.H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
2. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., and Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 378 (1995) 789-792 [Erratum in: Nature 1996;379:749]
3. Brody L.C., and Biesecker B.B. Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine 77 (1998) 208-226
4. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D.T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M.D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T.R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B.A., Gayther S.A., and Zelada-Hedman M. The Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62 (1998) 676-689
5. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Loman N., Olsson H., Johannsson O., Borg A., Pasini B., Radice P., Manoukian S., Eccles D.M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjäkoski K., Kallioniemi O.P., Thompson D., Evans C., Peto J., Lalloo F., Evans D.G., and Easton D.F. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 (2003) 1117-1130 [Erratum in: Am J Hum Genet 2003;73:709]
6. Liede A., Karlan B.Y., and Narod S.A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22 (2004) 735-742
7. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast and ovarian. MedGenMed 7 (2005) 60
8. Yoshida K., and Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95 (2004) 866-871
9. Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., Conte-Devolx B., Falchetti A., Gheri R.G., Libroia A., Lips C.J., Lombardi G., Mannelli M., Pacini F., Ponder B.A., Raue F., Skogseid B., Tamburrano G., Thakker R.V., Thompson N.W., Tomassetti P., Tonelli F., Wells Jr. S.A., and Marx S.J. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5671
10. Chandrasekharappa S.C., Guru S.C., Manickam P., Olufemi S.E., Collins F.S., Emmert-Buck M.R., Debelenko L.V., Zhuang Z., Lubensky I.A., Liotta L.A., Crabtree J.S., Wang Y., Roe B.A., Weisemann J., Boguski M.S., Agarwal S.K., Kester M.B., Kim Y.S., Heppner C., Dong Q., Spiegel A.M., Burns A.L., and Marx S.J. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 (1997) 404-407
11. Larsson C., Skogseid B., Öberg K., Nakamura Y., and Nordenskjöld M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332 (1988) 85-87
12. Thakker R.V., Bouloux P., Wooding C., Chotai K., Broad P.M., Spurr N.K., Besser G.M., and O'Riordan J.L. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med 321 (1989) 218-224
13. Carling T., Correa P., Hessman O., Hedberg J., Skogseid B., Lindberg D., Rastad J., Westin G., and Akerström G. Parathyroid MEN1 gene mutations in relation to clinical characteristics of non-familial primary hyperparathyroidism. J Clin Endocrinol Metab 83 (1998) 2960-2963
14. Bassett J.H., Forbes S.A., Pannett A.A., Lloyd S.E., Christie P.T., Wooding C., Harding B., Besser G.M., Edwards C.R., Monson J.P., Sampson J., Wass J.A., Wheeler M.H., and Thakker R.V. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 62 (1998) 232-244
15. Saslow D., Boetes C., Burke W., Harms S., Leach M.O., Lehman C.D., Morris E., Pisano E., Schnall M., Sener S., Smith R.A., Warner E., Yaffe M., Andrews K.S., and Russell C.A. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57 (2007) 75-89 [Erratum in: CA Cancer J Clin 2007;57:185]
16. Honda M., Tsukada T., Horiuchi T., Tanaka R., Yamaguchi K., Obara T., Miyakawa H., Yamaji T., and Ishibashi M. Primary hyperparathyroidism associated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. Intern Med 43 (2004) 310-314
17. Trump D., Farren B., Wooding C., Pang J.T., Besser G.M., Buchanan K.D., Edwards C.R., Heath D.A., Jackson C.E., Jansen S., Lips K., Monson J.P., O'Halloran D., Sampson J., Shalet S.M., Wheeler M.H., Zink A., and Thakker R.V. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89 (1996) 653-669 [Erratum in: QJM 1996;89:957-8]
18. Goggins M., Schutte M., Lu J., Moskaluk C.A., Weinstein C.L., Petersen G.M., Yeo C.J., Jackson C.E., Lynch H.T., Hruban R.H., and Kern S.E. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56 (1996) 5360-5364
19. Lal G., Liu G., Schmocker B., Kaurah P., Ozcelik H., Narod S.A., Redston M., and Gallinger S. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60 (2000) 409-416
20. Murphy K.M., Brune K.A., Griffin C., Sollenberger J.E., Petersen G.M., Bansal R., Hruban R.H., and Kern S.E. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62 (2002) 3789-3793
21. Couch F.J., Johnson M.R., Rabe K.G., Brune K., de Andrade M., Goggins M., Rothenmund H., Gallinger S., Klein A., Petersen G.M., and Hruban R.H. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16 (2007) 342-346
22. Bordi C., and Brandi M.L. Ductal adenocarcinoma of the pancreas in MEN-1-patients. Virchows Arch 432 (1998) 385-386
23. Bordi C., Falchetti A., Azzoni C., D'Adda T., Morelli A., Peracchia A., and Brandi M.L. Lack of allelic loss at the multiple endocrine neoplasia type 1 (MEN-1) gene locus in a pancreatic ductal (non-endocrine) adenocarcinoma of a patient with the MEN-1 syndrome. Virchows Arch 426 (1995) 203-208
24. Karges W., Maier S., Schmidt F., Gress T.M., and Boehm B.O. Role of the MEN1 tumor suppressor gene in human ductal pancreatic cancer. Cancer Lett 157 (2000) 51-55
25. Goh BK, Ooi LL, Kumarasinghe MP, Tan YM, Cheow PC, Chow PK, Chung YF, Wong WK. Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm. Pancreatology;6:520-6.
26. Canto M.I., Goggins M., Hruban R.H., Petersen G.M., Giardiello F.M., Yeo C., Fishman E.K., Brune K., Axilbund J., Griffin C., Ali S., Richman J., Jagannath S., Kantsevoy S.V., and Kalloo A.N. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4 (2006) 766-781
27. Yan L., McFaul C., Howes N., Leslie J., Lancaster G., Wong T., Threadgold J., Evans J., Gilmore I., Smart H., Lombard M., Neoptolemos J., and Greenhalf W. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 128 (2005) 2124-2130